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orientations (1,683 by telephone and 903 by electronic mail). Forty-nine percent of 
the requests were made by the patients, 45% by a family member and 2% by health 
care professionals. Among all requests, 77% were regarding patient´s rights and 23% 
were questions on health information. The 1,640 requests on patient rights were 
divided as follows: social rights (82%), problems related to access to treatments 
(10%), exams (3%) or physicians (3%). CONCLUSIONS: Our analysis showed that 
the demand for clarification regarding social rights and access to treatment reflect 
an unmet need for cancer patients and campaigns expanding the awareness of the 
population are warranted.
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OBJECTIVES: To determine how impactful patient-reported outcome (PRO) data 
from clinical trial programs are on market access decision making in oncology 
and other disease areas in decentralized markets. METHODS: A review of regula-
tory, health technology assessment (HTA), and third-party websites and published 
literature was the basis for six qualitative one-on-one interviews conducted with 
payer decision-makers (payers) in Brazil (1), Italy (1), Spain (1), and the United States 
(3) in 2014. RESULTS: Reviews conducted of HTA content and reimbursement deci-
sions indicate that HTA bodies have varying levels of familiarity and confidence 
in PRO data. All six payers indicated that it is worthwhile to collect PRO data in 
clinical trials for oncology, particularly in phase 3 and postmarketing studies. The 
payer in Spain was aware of a specific example where PRO data were crucial to 
decision-making for oncology. However, all six payers indicated that PRO data will 
increase in importance over the next 5 to 10 years and could be a key differentiator 
for new therapies. Payers did not differentiate the importance of PRO data by cancer 
type. All six payers indicated that the quality of the PRO evidence is paramount to 
consideration. In addition, they felt that PRO data currently have the most impact 
at the local level; one US payer noted there is significant opportunity to use PRO 
data to justify preferential product use and could be incorporated into hospital 
contracting. CONCLUSIONS: There are minimal requirements or guidelines specifi-
cally addressing whether and how health care decision-makers use PRO evidence; 
therefore, inclusion of PRO data in payer decision-making is currently determined 
on a case-by-case basis. There is growing recognition that the patient’s perspective 
is important in market access in decentralized markets.
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the dIsCoNNeCt BetweeN fuNdINg deCIsIoNs of CaNCeR dRugs aNd 
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OBJECTIVES: More and more pharmaceuticals receive indications that require the 
use of companion diagnostic tests to identify subgroups of patients who would 
benefit from the therapy. Many mutations have been identified in cancer and the 
choice of treatment frequently depends on the result of a specific companion diag-
nostic test. In Canada, the pan Canadian Oncology Drug Review (pCODR) assesses 
cancer drugs based on clinical evidence, cost-effectiveness and patient input, to 
make recommendations to Canada’s provinces in guiding their funding decisions. 
The objective of this study is to determine how pCODR assesses drugs that require 
a companion diagnostic. METHODS: All pCODR recommendations as of were 
reviewed and those involving the use of a companion diagnostic were identified. 
Analysis of these recommendations was conducted to determine how companion 
diagnostic tests accompanying cancer drugs were reviewed by pCODR. RESULTS: 
pCODR has received 52 submissions since its inception and 39 recommendations 
have been issued. Of these recommendations, 9 involved the use of a companion 
diagnostic test. Both positive and negative comments around companion diagnos-
tic tests were found among the pCODR recommendations. (Results will be tabu-
lated) CONCLUSIONS: pCODR recommendations are dedicated to cancer drugs. 
However for those drugs requiring a companion diagnostic, pCODR also looks at 
the information related to these tests, e.g. costs and utility. However, there is no 
submission process for companion diagnostic tests at pCODR. Consequently, there 
is opportunity for inconsistency among the pCODR recommendations for cancer 
drugs and associated companion diagnostic tests.
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OBJECTIVES: Biomarker-driven prescribing is potentially highly cost-effective as it 
directs premium-priced treatment towards most-likely responders. As competition 
intensifies and collective treatment costs rise, however, this study examined the 
US and EU5 reimbursement and prescribing landscape for personalized medicines, 
focusing on non-small-cell lung cancer (NSCLC). METHODS: 100 US and 250 EU5 
medical oncologists were surveyed regarding their prescribing of biomarker-driven 
treatments for NSCLC. In addition, 30 US managed care organization (MCO) phar-
macy directors (PDs) were surveyed, and 15 reimbursement-influencing EU5 payers 
interviewed. RESULTS: Among surveyed US payers, 27% most associate biomarker-
driven prescribing with premium drug pricing, versus 13% and 17% who cited high 
likelihood of efficacy, and focused prescribing in most-appropriate patients, respec-
tively. Furthermore, crizotinib and afatinib are excluded/NDC blocked by the larg-
est commercial plans of > 25% of respondents, while plans of even more list these 
agents as non-preferred and likely to stay non-preferred, overwhelmingly due to 
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OBJECTIVES: Our aim was to develop a conceptual framework in patients with 
locally recurrent or metastatic triple-negative breast cancer (TNBC) through a litera-
ture review and patient interviews. METHODS: A literature review on health-related 
quality of life (HRQoL) in advanced breast cancer was performed using the EMBASE 
database. Clinical experts were asked to identify key HRQoL concepts related to 
TNBC. Two trained psychologists conducted semi-structured individual interviews 
with patients with TNBC in the UK and France until saturation of concepts was 
reached. Patients were asked to cite important concepts related to the impact of 
disease on HRQoL and to rate them. Following ISPOR guidelines, qualitative analysis 
was performed by coding all patient responses. Code frequency and bother ratings 
were used to identify salient disease and treatment impact. RESULTS: Two clini-
cal experts and 28 patients were interviewed (age range, 26-83 years). Twenty-one 
patients (75%) had metastatic disease and 7 (25%) had locally recurrent cancer. 
Results of the patient interviews indicate that TNBC affects multiple dimensions 
of HRQoL: psychological functioning (shame/embarrassment, anger, worry, depres-
sion), role functioning (work limitation, social/leisure activities), energy levels, daily 
living and physical dimensions. Patients experienced distress because of fear of 
death, fear of disease progression, a changed body image, and concern about their 
loved ones. Patients associated a greater decrease in HRQoL with chemotherapy 
compared to radiotherapy and surgery as it resulted in a large range of impairments 
that impacted all relevant life domains: psychological and physical health, partici-
pation in social and occupational activities, and functioning in daily living. Coping 
strategies described by patients included living life day-by-day and prioritizing life 
differently. CONCLUSIONS: TNBC and its treatment have a profound effect on all 
aspects of patients’ lives. Results of this study were used to inform the inclusion of 
patient-reported outcome measures in phase 3 clinical development.
PCN130
INvaRIaNCe of QualIty of lIfe QuestIoNNaIRe eoRtC QlQC30 IN 
dIffeReNt CaNCeR INdICatIoNs
Viada C.1, Ballesteros J.2, Fors M.3, Luaces P.1, Sanchez L.1, Alvarez M.1, Frias A.1, Crombet T.1
1Center of Molecular Immunology, Havana, Cuba, 2University of the Basque Country, Leioa, Cuba, 
3National Center of Clinical Trials, Havana, Cuba
OBJECTIVES: To validate the short version of the QLQ-C30 obtained for patients 
with non-small-cell lung cancer in patients with head and neck, prostate, breast or 
cervix cancer METHODS: We analyzed data of 636 patients distributed: 237 diag-
nosed with head and neck cancer, 146 diagnosed with breast cancer, 140 diagnosed 
with cervix cancer and 113 diagnosed with prostate cancer. The analysis followed 
a 4-step approach. First, we conducted a Mokken nonparametric item response 
analysis to ascertain the QLQ-C30 dimensionality and separate several scale if 
appropriate. Second, we conducted a parametric Samejima’s graded response model 
(GRM) to assess the item characteristics and information for each scale. Third, we 
did a confirmatory factor analysis (CFA) to test the scales unidimensionality and 
to obtain standardized factor loadings to suggest a reduced version of the QLQ. 
Finally, we assessed the discriminative validity of the reduced version by using 
receiver-operator curve (ROC) analysis. RESULTS: In this study the reduction of 
the general questionnaire QLQ-C30 cancer 30 items to 6 scores are obtained. First it 
was found that 6 scores account for a 63.38% of the overall variability. Furthermore 
it was found that 6 score explained 62.3% of the variability in patients with head 
and neck cancer Nimotuzumab tratadados with a 65.53% for patients with pros-
tate cancer treated with Nimotuzumab or CIMAvaxEGF, a 61.80% for patients with 
breast cancer treated with NGcGM3 and 63.83% for patients with cervical cancer 
treated with Nimotuzumab. 6 scores obtained correspond to the score of physical, 
emotional and social functional scale and the scale of symptoms of nausea and 
vomiting. CONCLUSIONS: The EORTC reduced scale was invariant for each indica-
tions of cancer studied; it presents good psychometric properties and includes a 
unidimensional structure of patient-perceived quality of life.
CaNCeR – health Care use & Policy studies
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PatIeNts’ gRouPs aNd advoCaCy IN oNCology: awaReNess, suPPoRt 
aNd uNmet Needs
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OBJECTIVES: Patients’ groups and advocacy play an important role in the oncol-
ogy field. Understanding oncologic patients’ needs may improve prevention, early 
detection, quality-of-life and legal rights, reducing the burden of the disease. Few 
studies, however, have focused on the needs of this specific population in Brazil. The 
present analysis can contribute to develop an awareness campaign besides advocate 
to cancer patient needs. Our objective was to identify and describe the main needs 
of cancer patients in Brazil. METHODS: We analyzed the PAP program database 
from 01/2013 to 08/2014. This is a support and personalized counseling program 
dedicated to cancer patients and maintained by Oncoguia Institute, an independent 
nonprofit institution. We retrieved and described the applicants’ profiles (patient, 
family, specialty society, physicians, etc) and type of required information (patient 
rights, related to health/quality of life or access to diagnostic or treatment proce-
dures). RESULTS: In the aforementioned period, 2,214 applicants received 2,586 
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accurate incidence and prevalence data, but incidence estimates were found to be 
5-12 people/million/year in US. AL amyloidosis is associated with early mortality 
(median survival < 3 years in many series) and a 42-64% rate of non-response or 
progression. Costly complications of AL amyloidosis include disease-related organ 
failure. For example, kidney involvement is present in about 70% of patients, and 
rates of dialysis in patients with AL amyloidosis range from 5-18% with mean total 
12-month healthcare costs (inpatient, outpatient and indirect costs) for patients 
receiving dialysis being $99,776. There are no disease specific patient-reported out-
come (PROs) tools developed for AL amyloidosis, but patients report severe psycho-
logical distress, anxiety and also experience unintentional weight loss. There are 
no consistent clinical guidelines for treatment of AL amyloidosis especially after 
relapse as no drug has received FDA or EMA approval for this indication. Overall, 
limited efficacy and significant toxicity are still major concerns with current ther-
apy. CONCLUSIONS: Limited epidemiologic and health outcomes data exist in the 
literature for relapsed or refractory AL amyloidosis. Treatment options are insuf-
ficient. New therapies which offer better clinical outcomes with less toxicity are 
needed to improve patient care.
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OBJECTIVES: To develop consensus statements outlining the impact of endoscopic 
linear stapling device stability on potential complications of thoracic surgery and 
the stress/concern of thoracic surgeons. METHODS: An 8-member expert panel 
of practicing thoracic surgeons representing eight different countries participated 
in a Delphi panel process that included two anonymous surveys. The first survey 
included binary, multiple-response, and Likert scale type questions, which were 
then converted into affirmative statements for the second survey if an adequate 
number of respondents answered similarly. Consensus was defined a priori when 
≥ 70% of respondents agreed with the affirmative statement in survey 2. RESULTS: 
All 8 panelists (100%) completed surveys 1 and 2. Panelists unanimously agreed an 
endoscopic linear stapling device with improved stability would result in less stress/
concern for critical firings, surgeries where a fellow is being trained, and robot-
assisted surgeries requiring an assistant. Across all tissue types, all panelists agreed 
that reduced unintentional tissue/structure damage and reduced tension on tissue 
being fired upon may result from use of an endoscopic linear stapling device that 
provides improvement in stability. The panel unanimously considered endoscopic 
linear stapling device stability to have more clinical importance in VATS thoracic 
surgery compared to open thoracic surgery. CONCLUSIONS: Improved endoscopic 
linear stapling device stability is a critical component of thoracic surgery that is 
likely to result in more frequent positive surgical outcomes when compared to a 
device with greater instability.
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OBJECTIVES: Brazil and Mexico present an attractive opportunity for biosimilar 
manufacturers. The majority of patients in these key Latin American markets rely 
entirely on government-sponsored healthcare. These public healthcare systems 
continually strive to limit any premium costs in favor of increasing their subopti-
mal coverage, particularly of biologics for oncology. This study explores the expected 
impact of more cost-effective biosimilar alternatives on coverage and prescribing for 
key oncology indications in Brazil and Mexico. METHODS: Across Brazil and Mexico, 
100 medical oncologists and 60 hematologists were surveyed regarding their views 
on biosimilars for breast cancer, colorectal cancer, and Non-Hodgkin’s lymphoma, 
and on current and expected biologics prescribing patterns. Additionally, 8 payers 
who influence reimbursement at a national or regional/institutional level were inter-
viewed. RESULTS: Up to 41% of biologics-eligible public patients with a given tumor 
type do not currently receive a biologic, according to surveyed physicians in Brazil and 
Mexico. Respondents largely attributed low access to limited coverage for oncology 
biologics. Surveyed physicians and interviewed payers anticipate improved access 
to biologics upon biosimilar launch and an overall reduced burden from oncology 
biologics to the healthcare systems. Although surveyed specialists indicate some 
initial caution regarding the bioequivalence of biosimilars, they nevertheless fore-
see widespread biosimilar uptake. In Brazil’s public sector, for example, respondents 
expect that 70% of Herceptin-eligible breast cancer patients will receive biosimi-
lar trastuzumab. CONCLUSIONS: Oncology biosimilars should find fertile terrain 
in Brazil and Mexico. Automatic substitution in the public sector is likely, although 
interchangeability regulations are currently under discussion in both markets. Cost-
effectiveness combined with pharmacovigilance and robust long-term safety data 
will play a major role in the continuous uptake of biosimilars versus brands, with the 
latter securing reasonable market share only if priced competitively.
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OBJECTIVES: The breakthrough therapy designation (BTD) pathway aims to expedite 
approval of drugs for serious and life-threatening conditions. BTD has been awarded 
to numerous oncology agents in development. This study assessed the likely impact 
of BTD on payer and prescriber perceptions of novel therapies, and its potential to 
cost and/or insufficient clinical advantage over other therapies. Interviewed EU5 
payers, meanwhile, demand robust demonstration of improvement over existing 
agents for favorable health technology assessment (HTA) of personalized therapies, 
and increasingly seek cost-sharing schemes. However, most surveyed US and EU5 
oncologists preferentially prescribe biomarker-driven agents where appropriate (e.g. 
80% of US respondents most frequently use crizotinib first-line for ALK-positive 
NSCLC), despite prior authorization and reauthorization being commonly required 
in the US, and country-specific cost-containment measures (e.g. physician budgets 
in Germany and prescribing monitoring registries in Italy) being key prescribing 
hurdles in the EU5. CONCLUSIONS: Strong, demonstrable advantages over existing 
agents and pricing compromises are required to secure favorable reimbursement for 
biomarker-driven treatment. While prescribers favor personalized medicine, payers 
require proven value for money. Manufacturers must strive to optimize trial design 
to help convince payers to see beyond the price tag, and be prepared to balance price 
expectations with uptake potential to optimize market access.
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OBJECTIVES: To characterize the usage of Temozolomide (TMZ) in a real-world set-
ting among patients with glioblastoma. METHODS: Adult patients diagnosed with 
malignant brain cancer (ICD9-CM, 191.XX), who underwent brain-related surgery 
90 days prior to the first TMZ dose and had ≥ 24 months of continuous enrollment, 
were identified in the IMS Pharmetrics Lifelink Plus claims database. The TMZ + 
radiation subgroup was used to reflect glioblastoma patients and differentiate them 
from patients with lower-grade gliomas. Descriptive statistics were generated for 
patient demographics, insurance-related variables, co-diagnoses, concomitant 
medications, chemotherapy cycle-duration, and TMZ dose. The index date was 
defined as the first claim for TMZ, and certain variables were assessed for pre- 
and post-12 month periods. Statistical comparisons between pre- and post-index 
were performed using McNemar’s tests. RESULTS: A total of 1,126 patients met the 
inclusion criteria and the mean age was 52.7 yrs. (SD= 10.9). There was a significant 
increase in the use of concomitant medications (antianxiety, antidepressants, and 
antiemetic) as well as co-diagnoses (depression, fatigue, seizure/epilepsy, and hear-
ing loss) in the post-index period (p< 0.001). However, in this same period, corticos-
teroid and pain medication use significantly decreased as did the co-diagnoses of 
aphasia and headache (p< 0.001). TMZ mean starting dose, duration, and number 
of maintenance phase cycles was 154.4 mg (SD= 77.9), 46 days (SD= 12), and 7 cycles 
(SD= 3), respectively. Following the first dose, 73% of patients experienced a TMZ dose 
increase. CONCLUSIONS: Post-index, patients experienced a complex change in 
both concomitant medications and co-diagnoses, possibly reflecting both a decrease 
in tumor mass and side effects of the TMZ + radiation therapy. These initial findings 
warrant further investigation of TMZ as real-world standard-of-care in glioblastoma.
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OBJECTIVES: To characterize patients and treatment approaches relative to BRAF 
gene mutation testing. METHODS: An analysis of patient characteristics, diagnostic 
and treatment including BRAF testing, age, co-morbidities, number of tumor sites, 
hospital vocation and type of therapy used was conducted using the information 
included in the IMS Brogan Enhanced Tumor Study database from October 2013 to 
September 2014. RESULTS: Out of 343 stage IV melanoma patients, 239 were tested 
for BRAF mutations. 57% (136 pts.) were BRAF positive, 36% (87 pts.) BRAF negative 
and for 7% (16 pts.) results were not reported. Patients who were tested for BRAF 
tended to be less than 50 years of age (46% vs. 16%, p< 0.01), have none or only 1 
co-morbidity (87% vs. 70%, p< 0.01), have only 1 metastasis (34% vs. 45%, p< 0.05), 
and treated in an academic facility (74% vs. 50%, p< 0.01) compared to those who 
were not tested. BRAF negative patients were more often treated with ipilimumab 
compared to those who were not tested (42% vs. 10%, p< 0.01). CONCLUSIONS: 
Patients characteristics emerged as an important factor for determining diagnostic 
and treatment protocols for metastatic melanoma patients in Canada. Younger 
patients and those with more favorable disease characteristics are more likely to 
be tested for BRAF mutations and treated with ipilimumab in those without BRAF 
mutation. BRAF testing appears to be more prevalent in academic centers than in 
community hospitals.
PCN138
BuRdeN of systemIC lIght-ChaIN (al) amyloIdosIs: a systematIC 
lIteRatuRe RevIew
Mehta S.1, Cooke C.1, Gao X.1, Labotka R.2, Berg D.2, Parameswaran H.3, Lin H.M.2
1Pharmerit International, Bethesda, MD, USA, 2Millennium Pharmaceuticals, Inc., a wholly owned 
subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 3Medical College of 
Wisconsin, Milwaukee, WI, USA
OBJECTIVES: To conduct a systematic literature review on relapsed or refractory AL 
amyloidosis, focusing on clinical outcomes, epidemiology, health-related quality-
of-life (HRQoL) and economic aspects. METHODS: MEDLINE and EMBASE databases 
were searched for English-language articles published in the last 10 years using 
search terms including “Primary/Systemic amyloidosis”, “epidemiology/prevalence/
incidence”, “therapeutics/drug therapy/outcome”, ”patient-reported/quality-of-
life/satisfaction and “economics/cost” etc. Search results were manually reviewed, 
and relevant studies were selected for inclusion as appropriate. Additional refer-
ences were obtained from clinical conferences and the reference lists of selected 
articles. RESULTS: 1,141 articles were initially retrieved, and 58 were included in 
the current review. Given the rare nature of the disease, it was difficult to obtain 
